KR
KRRO
Korro Bio, Inc.
$10.73
+7.14%
$144.4M
No data for this timeframe.
Vol
Market Cap$144.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders8 funds
Inst. Value$6.3M
Inst. Activity3 buys / 3 sells
Insider Activity19B / 0S
Insider Net $$45.0M
SEC Reports5
Press Releases1
Recent Activity
May 19, 2026
SEC
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease affe
8-K — Impact 6/10
May 15, 2026
other
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bi
Apr 16, 2026
SEC
Korro Bio, Inc. filed a definitive proxy statement for its 2025 annual meeting, where shareholders will vote on director
DEFA14A — Impact 3/10
Mar 31, 2026
Insider
Lynx1 Capital Management LP bought 520 shares
10%+ Owner @ $10.60 ($5.5K)
Mar 23, 2026
SEC
Korro Bio, Inc. (KRRO) has had its Form S-3 shelf registration declared effective by the SEC, allowing the company to is
EFFECT — Impact 4/10
Mar 10, 2026
Insider
Mathers Edward T bought 207,100 shares
10%+ Owner @ $11.11 ($2.3M)
Mar 10, 2026
Insider
Mathers Edward T bought 242,945 shares
10%+ Owner @ $11.11 ($2.7M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
74,900 shares ($599.9K)
Price Targets
$19.89
+85.4% upside
Strong Buy
Current $10.73
Low $8.00
Median $22.00
High $30.00
9 analysts
$8.00
$30.00
Analyst Ratings
4Strong Buy
9Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 18, 2026 | Citigroup | INITIATE | Buy |
| Mar 13, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
| Mar 13, 2026 | Raymond James | UPGRADE | Market Perform → Outperform |
| Feb 19, 2026 | Clear Street | UPGRADE | Hold → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.18 ▲ +35.5% | $-1.71 — $-0.66 | 57% YoY | 8 |
| Next Q | $-1.20 ▲ +42.3% | $-1.75 — $-0.68 | 37% YoY | 8 |
| Current FY | $-5.18 ▲ +29.5% | $-7.08 — $-3.20 | 41% YoY | 8 |
| Next FY | $-5.06 ▲ +33.4% | $-7.14 — $-3.47 | 2% YoY | 7 |
Latest Reports
BULLISH
8-K
6/10
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease affe
May 19, 2026
NEUTRAL
DEFA14A
3/10
Korro Bio, Inc. filed a definitive proxy statement for its 2025 annual meeting, where shareholders will vote on director
Apr 16, 2026
NEUTRAL
Press
6/10
Korro Bio (KRRO) announced a $85 million PIPE financing led by Venrock Healthcare Capital Partners, with participation f
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $3.9M | — |
| TWO SIGMA INVESTMENTS, LP | $632.7K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $599.9K | ADD |
| MORGAN STANLEY | $558.5K | TRIM |
| FMR LLC | $303.2K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Lynx1 Capital | BUY | $5.5K |
| Mar 10, 2026 | Mathers Edward | BUY | $2.3M |
| Mar 10, 2026 | Mathers Edward | BUY | $2.7M |
| Mar 10, 2026 | Makhzoumi Mohamad | BUY | $2.7M |
| Mar 10, 2026 | Walker Paul | BUY | $2.3M |
8 institutional holders with $6.3M total value (780,855 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 489,639 | $3.9M | 62.7% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 78,984 | $632.7K | 10.1% | ADD +75.4% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 74,900 | $599.9K | 9.6% | ADD +85.4% |
| 4 | MORGAN STANLEY | 69,728 | $558.5K | 8.9% | TRIM -58.4% |
| 5 | FMR LLC | 37,857 | $303.2K | 4.8% | NEAR_EXIT -93.3% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 16,329 | $130.8K | 2.1% | TRIM -29.3% |
| 7 | WELLS FARGO & COMPANY/MN | 7,522 | $60.3K | 1.0% | ADD +45.5% |
| 8 | BANK OF AMERICA CORP /DE/ | 5,896 | $47.2K | 0.8% | ADD +25.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 40,400 | 74,900 | +85.4% | $599.9K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 167,494 | 69,728 | -58.4% | $558.5K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 563,681 | 37,857 | -93.3% | $303.2K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 23,101 | 16,329 | -29.3% | $130.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 5,170 | 7,522 | +45.5% | $60.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 4,704 | 5,896 | +25.3% | $47.2K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 81,733 | 167,494 | +104.9% | $8.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 36,746 | 64,455 | +75.4% | $3.1M | 2025-Q3 |
| UBS Group AG | DOUBLED | 18,581 | 53,103 | +185.8% | $2.5M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 17,776 | 23,101 | +30.0% | $1.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 28,156 | 4,704 | -83.3% | $225.3K | 2025-Q3 |
| MORGAN STANLEY | ADD | 43,100 | 81,733 | +89.6% | $1.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 45,700 | — | $570.8K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 36,746 | — | $459.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,541 | 28,156 | +520.0% | $351.7K | 2025-Q2 |
| UBS Group AG | TRIM | 74,211 | 18,581 | -75.0% | $232.1K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 369,733 | 253,250 | -31.5% | $4.4M | 2025-Q1 |
| MORGAN STANLEY | ADD | 28,562 | 43,100 | +50.9% | $750.4K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 529,173 | 369,733 | -30.1% | $14.1M | 2024-Q4 |
| UBS Group AG | DOUBLED | 9,730 | 73,039 | +650.7% | $2.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 2,561 | 3,392 | +32.4% | $129.1K | 2024-Q4 |
| MORGAN STANLEY | ADD | 13,021 | 23,355 | +79.4% | $780.5K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 17,567 | — | $587.1K | 2024-Q3 |
16 unique insiders with 19 transactions. Net insider value: $45.0M ($45.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Lynx1 Capital Management LP | 10%+ Owner | BUY | 520 | $10.60 | $5.5K |
| Mar 10, 2026 | Mathers Edward T | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Mathers Edward T | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | Makhzoumi Mohamad | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | Walker Paul Edward | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | SANDELL SCOTT D | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | Makhzoumi Mohamad | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Walker Paul Edward | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | SANDELL SCOTT D | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Behbahani Ali | Director | A | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | Chang Carmen | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Florence Anthony A. Jr. | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | Behbahani Ali | Director | A | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Chang Carmen | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | Florence Anthony A. Jr. | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Yang Rick | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | New Enterprise Associates 17, L.P. | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | Yang Rick | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Mar 10, 2026 | New Enterprise Associates 17, L.P. | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | BASKETT FOREST | 10%+ Owner | BUY | 242,945 | $11.11 | $2.7M |
| Mar 10, 2026 | BASKETT FOREST | 10%+ Owner | BUY | 207,100 | $11.11 | $2.3M |
| Feb 2, 2026 | Cerio Jeffrey | General Counsel | A | 23,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Dolan Oliver | Senior Vice President, Finance | A | 15,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Vincent Loic A | Chief Scientific Officer | A | 35,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Aiyar Ram | President and CEO | A | 40,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Aiyar Ram | President and CEO | A | 80,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Chappell Todd | Chief Operating Officer | A | 38,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.6/10.
BULLISH
8-K
6/10
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a
May 19, 2026
NEUTRAL
DEFA14A
3/10
Korro Bio, Inc. filed a definitive proxy statement for its 2025 annual meeting, where shareholders w
Apr 16, 2026
NEUTRAL
EFFECT
4/10
Korro Bio, Inc. (KRRO) has had its Form S-3 shelf registration declared effective by the SEC, allowi
Mar 23, 2026
BEARISH
S-3
7/10
Korro Bio has filed a shelf registration (S-3) to register the resale of up to 7,650,764 shares of c
Mar 13, 2026
BULLISH
CLUSTER
8/10
Multiple insiders and institutional investors in Korro Bio (KRRO) collectively purchased over $20 mi
Mar 13, 2026
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 4 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.89 mean target
+85.4% upside
Strong Buy (1.40)
$8.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $10.73 |
| Target Low | $8.00 |
| Target Mean | $19.89 |
| Target Median | $22.00 |
| Target High | $30.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.18 | $-1.71 | $-0.66 | 57.1% | +35.5% | 0↑ 1↓ | $0.0B | -88.6% | 8 |
| Next Q 2026-09-30 |
$-1.20 | $-1.75 | $-0.68 | 37.4% | +42.3% | 0↑ 1↓ | $0.0B | -84.7% | 8 |
| Current FY 2026-12-31 |
$-5.18 | $-7.08 | $-3.20 | 41.2% | +29.5% | 0↑ 1↓ | $0.0B | -91.3% | 8 |
| Next FY 2027-12-31 |
$-5.06 | $-7.14 | $-3.47 | 2.4% | +33.4% | 0↑ 1↓ | $0.0B | -55.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.176 | |
| 7d ago | $-1.151 | -0.025 |
| 30d ago | $-1.824 | +0.648 |
| 60d ago | $-1.824 | +0.648 |
| 90d ago | $-2.011 | +0.835 |
9 analyst firms have rated this stock: 8 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 18, 2026 | Citigroup | INITIATE | — | Buy |
| Mar 13, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Mar 13, 2026 | Raymond James | UPGRADE | Market Perform | Outperform |
| Feb 19, 2026 | Clear Street | UPGRADE | Hold | Buy |
| Feb 17, 2026 | William Blair | UPGRADE | Market Perform | Outperform |
| Jan 29, 2026 | Chardan Capital | UPGRADE | Neutral | Buy |
| Jan 29, 2026 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Jan 29, 2026 | Piper Sandler | UPGRADE | Neutral | Overweight |
| Jan 28, 2026 | Oppenheimer | UPGRADE | Perform | Outperform |
| Jan 28, 2026 | Cantor Fitzgerald | UPGRADE | Neutral | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 9 | 3 | 0 | 0 | 81% | |
| Apr 1, 2026 | 4 | 8 | 4 | 0 | 0 | 75% | |
| Mar 1, 2026 | 4 | 8 | 4 | 0 | 0 | 75% | |
| Feb 1, 2026 | 3 | 6 | 7 | 0 | 0 | 56% | |
| Jan 1, 2026 | 3 | 3 | 10 | 0 | 0 | 38% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 17, 2026
Clinical Trial
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Phase Phase 2 — TERMINATED
May 15, 2026
other
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonu
May 7, 2026
earnings
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging
May 5, 2026
earnings_calendar
KRRO Q1 2026 Earnings Scheduled — 2026-05-05
Apr 16, 2026
other
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
<p align="justify">CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company develo
Apr 10, 2026
other
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing
Mar 9, 2026
offering
Korro Announces Oversubscribed $85 Million Private Placement
<p align="left">CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing